# Residual Hypermethylation in Early Stage Non-Small Cell Lung Cancer (NSCLC) As Part of Adjuvant Therapy and Preventive Strategy

> **NCT01209520** · NA · COMPLETED · sponsor: **University of Miami** · enrollment: 6 (actual)

## Conditions studied

- Lung Cancer
- Non Small Cell Lung Carcinoma
- Hypermethylation

## Interventions

- **DRUG:** Cisplatin
- **DRUG:** Carboplatin
- **DRUG:** Paclitaxel
- **DRUG:** Vidaza
- **PROCEDURE:** Tumor Specimen for Methylation Analysis
- **PROCEDURE:** Blood Sample for Methylation Analysis
- **DRUG:** Vinorelbine
- **DRUG:** Docetaxel
- **DRUG:** Pemetrexed

## Key facts

- **NCT ID:** NCT01209520
- **Lead sponsor:** University of Miami
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-07
- **Primary completion:** 2013-12
- **Final completion:** —
- **Target enrollment:** 6 (ACTUAL)
- **Last updated:** 2015-02-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01209520

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01209520, "Residual Hypermethylation in Early Stage Non-Small Cell Lung Cancer (NSCLC) As Part of Adjuvant Therapy and Preventive Strategy". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01209520. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*